In the news | 4th June 2013
R&D: Are true drug breakthroughs a thing of the past?
Fierce Biotech
June 2013
One of the most intense discussions at ASCO over the past few days has zeroed in on the FDA’s new “breakthrough” drug status. The agency is offering developers essentially an open door at the FDA to any program that qualifies, urging on R&D teams with quick responses and help adapting trials and hurrying the review process with the aim of getting more “transformative” drugs to the market faster.
More news
New process definition capabilities in PIMS further enhance quality assurance and “right-first-time” initiatives for pharma manufacturers
New process definition capabilities in PIMS 5.1, further enhance quality assurance and “right-first-time” initiatives for pharma manufacturers.
Tradeshow | European BioAnalysis Forum | Nov 2023
Come and see us at Festival of Biologics in Basel. Visit our booth 604 and hear Marc Smith, Director of Strategic Solutions, speak.
Software validation keeps GxP systems current and speeds up time-to-market
Requirements to maintain a GxP environment means researchers must conduct software validation on any updated software so it continues to meet users’ needs.
Tradeshow | Cell UK 2023 London | November, 2023
Talk on “Streamlining upstream development: an integrated digital backbone to combine product and process insight for a more efficient path to success.”